Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)

Journal of Clinical and Translational Hepatology, Год журнала: 2024, Номер 000(000), С. 000 - 000

Опубликована: Ноя. 4, 2024

With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China, dysfunction-associated non-alcoholic fatty liver disease has become most prevalent chronic disease. This condition frequently occurs Chinese patients with alcoholic hepatitis B. To address impending public health crisis its underlying issues, Society Hepatology Medical Association convened a panel clinical experts to revise update "Guideline prevention treatment (2018, China)". The new edition, titled for (Version 2024)", offers comprehensive recommendations on key including screening monitoring, diagnosis evaluation, treatment, follow-up steatotic Metabolic is now preferred English term used interchangeably Additionally, guideline emphasizes importance multidisciplinary collaboration among hepatologists other specialists manage cardiometabolic disorders effectively.

Язык: Английский

---

Metabolic dysfunction-associated steatotic liver disease in adults

Nature Reviews Disease Primers, Год журнала: 2025, Номер 11(1)

Опубликована: Март 6, 2025

Язык: Английский

---

Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Фев. 18, 2025

ABSTRACT Background The continuum of metabolic syndrome encompasses a spectrum dysfunctions impacting obesity‐linked insulin resistance, glucose homeostasis, lipid metabolism and pro‐inflammatory immune responses. global prevalence diseases, including diabetes, chronic liver disease, cardiometabolic disease kidney has surged in recent decades, contributing significantly to population mortality. Metabolic dysfunction‐associated steatotic (MASLD), formerly known as non‐alcoholic fatty is leading cause worldwide. MASLD poses significant health challenge with its rising prevalence, placing substantial burden on healthcare systems, impacts patient well‐being incurs economic costs. Addressing requires comprehensive understanding interconnected factors, implications. Lack awareness, imprecise non‐invasive diagnostic methods ineffective preventive interventions are core components the MASLD‐related problem. Aim aim this article was summarise from payer's perspective. Methods We carried out review MASLD. These topics led discussions insights by an expert panel during 7th Continuum Roundtable meeting, which took place November 2023. This meeting focused burden, patient‐reported outcomes economics, payor societal perspectives, aimed identify opportunities for improving care, optimise resource allocation mitigate overall impact individuals society related During roundtable, emphasis emerged need greater awareness strategic deployment diagnostic, therapeutic preventative measures address effectively. Conclusion high growing. Prioritising prevention dysregulation timely can yield holistic strategy combat MASLD, progression potentially lower Trial Registration: NCT06309992

Язык: Английский

---

Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024

Gastroenterology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

---

Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions

Journal of Hepatology, Год журнала: 2023, Номер 80(2), С. 335 - 351

Опубликована: Окт. 24, 2023

Язык: Английский

---

Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(15), С. 12232 - 12232

Опубликована: Июль 31, 2023

Non-alcoholic fatty liver disease (NAFLD) affects about 20-40% of the adult population in high-income countries and is now a leading indication for transplantation can lead to hepatocellular carcinoma. The link between gut microbiota dysbiosis NAFLD clearly established. Through analyses with shotgun metagenomics, we observe that compared healthy controls, Adlercreutzia equolifaciens depleted patients diseases such as NAFLD. Its abundance also decreases progresses eventually disappears last stages indicating strong association severity. Moreover, show A. possesses anti-inflammatory properties, both vitro vivo humanized mouse model Therefore, our results demonstrate severity presence its actions. Counterbalancing this bacterium may be promising live biotherapeutic strategy diseases.

Язык: Английский

---

Gastrointestinal cancers in lean individuals with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

Liver International, Год журнала: 2023, Номер 44(1), С. 6 - 14

Опубликована: Окт. 13, 2023

Abstract Background & Aims Obesity and non‐alcoholic fatty liver disease (NAFLD) are known risk factors for gastrointestinal (GI) cancers. However, GI carcinogenesis in lean NAFLD patients remains unclear. This systematic review meta‐analysis aims to investigate the association between cancer risk. Methods PubMed, Embase Cochrane Library databases were systematically searched (from inception date April 2023) cohort studies assessing cancers (body mass index [BMI] < 25 kg/m 2 or 23 Asians) non‐lean (BMI ≥25 ≥ individuals. Data from eligible extracted, was carried out using a random effects model obtain ratios (RRs) with 95% confidence intervals (CIs). Subgroup analyses, meta‐regressions sensitivity analyses also performed. study registered PROSPERO (CRD42023420902). Results Eight 56,745 individuals (11% lean) 704 cases of incident included. Lean associated higher hepatic (RR 1.77, CI 1.15–2.73), pancreatic 1.97, 1.01–3.86) colorectal 1.53, 1.12–2.09), compared NAFLD. No significant differences observed oesophagus, gastric, biliary small intestine Conclusions shows that have an increased liver, patients, emphasizing need explore tailored prevention strategies this specific patient group. Further research is required mechanisms underlying

Язык: Английский

---

Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development

Pharmacological Research, Год журнала: 2023, Номер 196, С. 106925 - 106925

Опубликована: Сен. 13, 2023

With changing lifestyles, non-alcoholic fatty liver disease (NAFLD) has become the most prevalent worldwide. A substantial increase in incidence, mortality, and associated burden of NAFLD-related advanced is expected. Currently, initial diagnosis NAFLD still based on ultrasound there no approved treatment method. Lipid-lowering drugs, vitamin supplementation, lifestyle improvement treatments are commonly used clinical practice. However, lipid-lowering drugs can produce poor patient compliance specific adverse effects. Therefore, exploration bio-diagnostic markers active lead compounds for development innovative urgently needed. More more studies have reported anti-NAFLD effects mechanisms natural products (NPs), which an important source new drug to treat due their high activity low side At present, berberine silymarin been by US FDA enter phase IV studies, demonstrating potential NPs against NAFLD. Studies found that regulation lipid metabolism, insulin resistance, oxidative stress, inflammation-related pathways may play roles process. continuous updating technical means scientific theories, in-depth research targets provide possibilities find drugs. As we know, FXR agonists, PPARα dual CCR2/5 inhibitors gradually coming stage Whether exert regulating these or some unknown remains be further studied. study reviewed targets. Some works discovery docking were also discussed. It hoped this review reference values non-invasive diagnostic clinic.

Язык: Английский

---

Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review

Cancers, Год журнала: 2024, Номер 16(6), С. 1214 - 1214

Опубликована: Март 20, 2024

The prevalence of metabolic-associated fatty liver disease (MAFLD) is increasing globally due to factors such as urbanization, obesity, poor nutrition, sedentary lifestyles, healthcare accessibility, diagnostic advancements, and genetic influences. Research on MAFLD HCC risk factors, pathogenesis, biomarkers has been conducted through a narrative review relevant studies, with focus PubMed Web Science databases exclusion criteria based article availability language. Steatosis marks the early stage MASH advancement, commonly associated metabolic syndrome obesity type 2 diabetes. Various mechanisms, including heightened lipolysis, hepatic lipogenesis, consumption high-calorie diets, contribute accumulation lipids in liver. Insulin resistance pivotal development steatosis, it leads release free acids from adipose tissue. Natural compounds hold promise regulating lipid metabolism inflammation combat these conditions. Liver fibrosis serves significant predictor progression development, underscoring need target treatment approaches. Risk for MASH-associated encompass advanced fibrosis, older age, male gender, syndrome, predispositions, dietary habits, emphasizing requirement efficient surveillance measures. Considering important further studies determine biochemical impact order establish targeted therapies that can prevent or reduce MASH, indirectly decreasing HCC.

Язык: Английский

---

A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

Hepatology International, Год журнала: 2024, Номер 18(4), С. 1178 - 1201

Опубликована: Июнь 15, 2024

Язык: Английский

---